Savara SVRA
NASDAQ SVRA
$4.86 -0.19 (-3.77%)
As of: Oct 2, 2026 · 11:18 AM EDT

Savara (SVRA) Liabilities and Shareholders Equity (2010 - 2026)

Updated

Savara (SVRA) posted Liabilities and Shareholders Equity of $192.14 million for Q2 2026, up 17.3% from $163.77 million a year earlier but down 13.3% from the prior quarter.

Analysis

Savara (SVRA) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

At the end of FY2025, Savara's Liabilities and Shareholders Equity came in at $253.44 million, up 19.1% from FY2024.

  • Annual Liabilities and Shareholders Equity has increased for three consecutive years, with a five-year compound annual growth rate of 21.0% (FY2020 to FY2025).
  • In prior years, Savara's Liabilities and Shareholders Equity was $212.88 million in FY2024 (+19.9%), $177.56 million in FY2023 (+27.0%), $139.78 million in FY2022 (-20.9%) and $176.6 million in FY2021 (+80.7%).
  • Quarterly Liabilities and Shareholders Equity has run from a low of $119.83 million in Q2 2023 to a high of $253.44 million in Q4 2025 over five years.
  • On a year-over-year basis, Liabilities and Shareholders Equity has increased in each of the last three quarters, with growth averaging 12.5% over the last eight quarters.
  • The strongest year-over-year quarter for Liabilities and Shareholders Equity in the past five years was Q4 2021, with growth of 80.7%; the weakest was Q3 2025, with a decline of 41.0%.
  • According to Business Quant data, Liabilities and Shareholders Equity for the three prior quarters was $221.65 million (Q1 2026), $253.44 million (Q4 2025) and $140.92 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Savara 1.06 Bn 1.06 Bn - 192.14 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 192.14 Mn
Mar 31, 2026 221.65 Mn
Dec 31, 2025 253.44 Mn
Sep 30, 2025 140.92 Mn
Jun 30, 2025 163.77 Mn
Mar 31, 2025 189.32 Mn
Dec 31, 2024 212.88 Mn
Sep 30, 2024 238.82 Mn
Jun 30, 2024 139.67 Mn
Mar 31, 2024 158.30 Mn
Dec 31, 2023 177.56 Mn
Sep 30, 2023 182.07 Mn
Jun 30, 2023 119.83 Mn
Mar 31, 2023 129.36 Mn
Dec 31, 2022 139.78 Mn
Sep 30, 2022 147.76 Mn
Jun 30, 2022 156.78 Mn
Mar 31, 2022 166.21 Mn
Dec 31, 2021 176.60 Mn
Sep 30, 2021 187.27 Mn
API Access

Savara Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=SVRA&period=max&api_key=YOUR_API_KEY